Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
GLP1 + Cagrilintide Research Administration Common Study Populations Clinical trials have enrolled diverse participant groups: Adults with obesity BMI 30 kg/m squared or greater without diabetes (REDEFINE 1) Adults with overweight and comorbidities BMI 27 kg/m squared or greater with at least one weight-related condition Adults with type 2 diabetes BMI 27 kg/m squared or greater with established diabetes (REDEFINE 2) Age range Primarily adults aged 18-75 years across trials Geographic diversity Multi-national trials across North America, Europe, Asia, and other regions Exclusion criteria typically included type 1 diabetes, recent cardiovascular events, severe renal or hepatic impairment, history of pancreatitis, and medications causing significant weight changes
Reduces the appearance of fine lines & wrinkles
Your glow is within arms reach with this power-packed skincare routine
Theres not enough evidence available regarding the safety of chanca piedra during pregnancy or breastfeeding
If you have sensitive skin or any pre-existing skin condition, consult a healthcare professional before use
A 2023 Phase 2 trial reported 24.2% average weight loss at 48 weeks in the 12 mg group
